Abstract: Apparatus useful in sensing intraocular pressure are provided. The apparatus generally include a rigid tube defining a hollow through space sized and adapted to allow a flexible catheter of a pressure sensor or transducer used to sense IOP to pass in or in fluid communication with the hollow through space. The apparatus includes stabilizing structure for facilitating fixing of the tube in a desired position or angular orientation within the eye. The present apparatus more effectively maintains the position or angle of the flexible catheter or distal end portion of the pressure sensor or in the eye relative to a similar pressure sensor transducer including a flexible catheter without the rigid tube and/or without the stabilizing structure.

Abstract: Apparatus and methods are provided for delivering therapeutic agents to an eye, for example, into a vitreous of any eye. The apparatus generally includes a conduit coupled to a holder, such as a syringe, containing a therapeutic composition. The conduit includes a distal region having at least one sidewall opening spaced apart from a distal tip and structured to deliver the composition into the vitreous, for example, directly into a peripheral region of the vitreous. The conduit may have a closed distal tip or an open distal tip.

Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.

Abstract: Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure.